Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.63 |
| ▸ | TNIK | Q9UKE5 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.45 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23906239 | 1.00 | IGF1R (0.63) | IGF1RTNIKKCNH2MAPK10CCNT1 | |
| SCHEMBL23906917 | 0.88 | JAK2 (0.51) | IGF1RMAPK10PLK4MAPK9JAK2 | |
| SCHEMBL30086450 | 0.88 | JAK2 (0.51) | IGF1RMAPK10PLK4MAPK9JAK2 | |
| SCHEMBL30086328 | 0.85 | PLK4 (0.65) | IGF1RTNIKMAPK10CCNT1CDK9 | |
| SCHEMBL23887678 | 0.85 | PLK4 (0.65) | IGF1RTNIKMAPK10CCNT1CDK9 | |
| SCHEMBL23906593 | 0.83 | EGFR (0.56) | IGF1RZAP70 | |
| SCHEMBL30086534 | 0.83 | EGFR (0.56) | IGF1RZAP70 | |
| SCHEMBL28965387 | 0.81 | EPHB4 (0.53) | IGF1RPLK4MAPK8MTOR | |
| SCHEMBL23906708 | 0.79 | JAK2 (0.56) | IGF1RKCNH2CCNT1CDK9JAK2 | |
| SCHEMBL30086462 | 0.79 | JAK2 (0.56) | IGF1RKCNH2CCNT1CDK9JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372015-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | IGF1R 558/4885TNIK 534/4885KCNH2 4092/4885 |
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | IGF1R 558/4885TNIK 534/4885KCNH2 4092/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | IGF1R 558/4885TNIK 534/4885KCNH2 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.